Bayer is breaking into the irritable bowel syndrome (IBS) therapy market with the acquisition of HiDoc Technologies, which ...

Bayer initiates phase I study with SOS1 inhibitor, BAY3498264 in patients with advanced KRAS-mutated tumours: Berlin Saturday, December 14, 2024, 13:00 Hrs [IST] Bayer announced i ...

Epigenic, Immunocan have officially moved into Bayer Co.Lab, and AccurEdit Therapeutics will join early next month. Photo: ...

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and ...

“We look forward to advancing the programme through clinical development, strengthening Bayer’s innovative oncology treatments by broadening the ... We are not an agent for these third parties nor do ...